N
Patient 1
APOC INCIDENT # (B)(4). APOC LABELING WILL BE EVALUATED DURING THE INVESTIGATION AS PERTAINING TO THE EVENT.
| Seq | Brand | Generic | Manufacturer | Product code | Model | Catalog | Lot | PMA | 510(k) | Implant | Evaluated | Availability |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | I-STAT CG4+ CARTRIDGE | CG4+ CARTRIDGE | ABBOTT POINT OF CARE | KHP | NA | 03P85-25 | Y | N |
| Sequence | Received | Treatment | Outcome |
|---|---|---|---|
| 1 | 2018-12-19 | 0 | 1. D |
Patient 1
APOC INCIDENT # (B)(4). APOC LABELING WILL BE EVALUATED DURING THE INVESTIGATION AS PERTAINING TO THE EVENT.
Patient 1
ON 12/07/2018, ABBOTT POINT OF CARE WAS CONTACTED BY A CUSTOMER REGARDING I-STAT CG4+ CARTRIDGES (LOT# UNK) THAT YIELDED SUSPECTED DISCREPANT RESULTS ON AN (B)(6) PATIENT WITH DIABETES. THE CUSTOMER STATED THAT THE PATIENT WAS ALREADY VERY CRITICAL WHEN ADMITTED AND LATER EXPIRED. CAUSE OF DEATH IS UNKNOWN AT THE TIME OF THIS REPORT. THERE WAS NO ADDITIONAL PATIENT INFORMATION AVAILABLE AT THE TIME OF THIS REPORT. METHOD, DATE, RESULT, SAMPLE: I-STAT, (B)(6) 2018,
Patient 1
APOC INCIDENT # (B)(4). THE INVESTIGATION WAS COMPLETED ON 02/19/2019. A REVIEW OF THE DEVICE HISTORY RECORD (DHR) CONFIRMED THE CARTRIDGE LOT MET FINISHED GOODS (FG) RELEASE CRITERIA. RETAINED TESTING MET THE ACCEPTANCE CRITERIA OUTLINED IN APPENDIX 1 OF Q04.01.003 REV. AC (PRODUCT COMPLAINT LEVEL 2 AND LEVEL 3 INVESTIGATION PROCEDURE). NO DEFICIENCY HAS BEEN DETERMINED FOR CG4+ LOT M18163A.
Patient 1